21st.BIO cracks the code for animal-free dairy protein with BLG Essential+

21st.BIO has announced that it has secured self-affirmed GRAS status for its BLG Essential+, an animal-free version of beta-lactoglobulin, a powerful dairy protein. This achievement unlocks the US market for companies seeking to harness the exceptional qualities of BLG in their products.

It's been less than two years since 21st.BIO embarked on creating the BLG Essential+ strain and production process. This rapid turnaround showcases the power of its expertise and industry-leading precision fermentation platform.

Beta-lactoglobulin, the star of the show, is the dominant protein found in whey. Food producers are drawn to its impressive nutritional profile and its ability to elevate food formulations.

BLG Essential+ boasts a higher concentration of essential and branched-chain amino acids compared to commercially available whey protein isolates. This, particularly the increased leucine content (45% more!), makes it a champion for muscle synthesis.

BLG Essential+ is a dream ingredient for product developers. It's flavorless, tolerates a wide range of pH levels, and remains stable under heat. This opens doors to exciting creations, from protein drinks with crystal clarity to innovative alternative dairy products and bakery delights.

21st.BIO's vision extends beyond their creation. Companies participating in their development program gain access to the world's most advanced production strains and processes for BLG Essential+, with ongoing optimizations. They also receive support throughout the upscaling journey, from pilot production to full-scale manufacturing. This empowers a diverse range of players, from food-tech startups to established ingredients giants. BLG Essential+ marks the first of many protein ingredients 21st.BIO plans to introduce using this groundbreaking model.

21st.BIO leverages their proven track record and productive microorganisms (licensed from Novonesis) to deliver solutions at an unprecedented pace. This translates to bypassing years of development and regulatory hurdles, allowing companies to directly enter the US market. But that's not all! 21st.BIO empowers them to produce a vast array of proteins – from food and material science applications to agriculture and biopharmaceuticals. They ensure industrial-scale production for widespread availability and cost-effectiveness. Companies within their program benefit from continual strain and process improvements for maximized commercial appeal.

21st.BIO goes beyond simply providing technology; they are partners in their customers' success stories.  "We offer access to skills and technology unavailable elsewhere," explains Per Falholt, Co-founder & CSO of 21st.BIO.

Thomas G. Schmidt, Co-founder & CEO added, "We're not just a supplier, we're a team dedicated to your product journey, from concept to full-scale manufacturing. We deliver products, not projects. Our goal is to empower our customers to focus on what matters: application, business development, cost-effective production, and innovation. This philosophy permeates our entire business model. Our success at 21st.BIO hinges on our customers' market triumphs, not just project completion."

21st.BIO offers comprehensive support throughout development. Their expertise spans strain development, fermentation processes, purification protocols, pilot production, upscaling guidance, and even regulatory navigation for market entry. Their pipeline extends beyond BLG Essential+, with additional proteins in development for diverse applications across food, materials, agriculture, and beyond.